Women's Cancers: Prevention, Screening & Treatment
Session Overview
The field of women’s cancers encompasses a complex and rapidly evolving landscape of prevention, early detection, molecular stratification, and targeted treatment. This domain integrates public health initiatives, translational genomics, and innovative therapeutics to address malignancies with profound implications for reproductive health, survivorship, and quality of life. This session brings together multidisciplinary perspectives to examine the continuum of care—from primary prevention and screening to novel treatments and long-term survivorship—for breast, gynecologic, and other cancers affecting women.
Why This Session Matters Now
Advancements in molecular profiling, targeted therapies, and immunotherapy are fundamentally reshaping the prognosis and management of women’s cancers. Concurrently, the successful implementation of global vaccination and screening programs for HPV-related diseases highlights the powerful impact of public health strategies. This session addresses the critical need to integrate these parallel advances—connecting population-level prevention with precision oncology—while also focusing on the unique reproductive and quality-of-life considerations that define comprehensive care for women with cancer.
Key Scientific and Clinical Themes
Breast Cancer Biology, Screening, and Genetics
Exploration of the molecular heterogeneity of breast cancer, risk assessment strategies, advances in genetic testing (e.g., BRCA), and evolving paradigms in population-based and personalized screening.
Cervical Cancer Prevention and HPV-Related Disease
Examination of the global impact of HPV vaccination, innovations in cervical screening techniques, and management of pre-invasive and invasive disease, with a focus on equitable access and elimination strategies.
Gynecologic Malignancies: Endometrial and Ovarian Cancer
Discussion on the rising incidence of endometrial cancer, molecular classification schemes, early detection challenges in ovarian cancer, and the expanding role of targeted therapies and PARP inhibitors.
Oncofertility and Reproductive Health in Cancer Care
Focus on the preservation of fertility and management of endocrine health before, during, and after cancer treatment, addressing a core component of patient-centered care for young women.
Cancer Survivorship and Long-Term Outcomes
Holistic consideration of the physical, psychological, and metabolic long-term effects of cancer treatment, and the development of care models to optimize health and quality of life in survivorship.
Innovations in Cancer Detection and Therapeutics
Review of emerging technologies in early detection, such as liquid biopsy, and novel therapeutic agents, including antibody-drug conjugates and next-generation targeted inhibitors, that are altering treatment pathways.
Nature of Research in This Field
Research in women’s cancers is characterized by its vast scale and translational immediacy. It spans large-scale epidemiological studies, biomarker-driven clinical trials, and health services research focused on care delivery. The field is marked by a continuous cycle of discovery—from identifying genetic risk factors and molecular targets to rapidly testing novel agents in clinical settings—followed by intensive efforts to synthesize evidence and integrate findings into global guidelines and diverse clinical practices.
Who Should Attend
This session is designed for:
- Medical, gynecologic, and radiation oncologists specializing in women’s cancers
- Researchers in cancer biology, epidemiology, and translational therapeutics
- Public health professionals involved in cancer prevention and screening programs
- Surgeons, genetic counselors, and fertility specialists
- Allied health professionals dedicated to survivorship and supportive care
Session Perspective
The management of women’s cancers requires a dual focus: the macroscopic view of public health prevention and the microscopic view of personalized tumor biology. This session provides a comprehensive platform to connect these perspectives, examining how breakthroughs in virology, genetics, and drug development are being translated into strategies that reduce global cancer burden and improve individual outcomes. The discussion aims to bridge disciplines, from basic science to community implementation, fostering collaborative approaches to one of the most significant areas of women’s health.
If your research aligns with this session, we invite you to submit an abstract for consideration.
